Hints and tips:
Related Special Reports
...This state-by-state strategy had previously been attempted by tobacco and asbestos companies when facing a wave of lawsuits, said Daniel Hinkle, senior state affairs counsel for the American Association...
...The chain was successful in raising about £10mn from this group, with some of the proceeds used to cover the cost of buying out Ahsan, people familiar with the matter told the FT’s Oliver Barnes and Daniel...
...News round-up Roche agrees $7.1bn deal for Telavant to boost drug pipeline (FT) Big university endowments hampered by start-up writedowns (Wall Street Journal) Web Summit CEO resigns after comments on...
...“If we see something large that is attractive, we can chase it, but we don’t feel pressure to do that,” Roche told DD in an interview....
...Franz Humer, former chair of Diageo and Roche, joined the board in March....
...To celebrate this, the enchanting Daniel Katz Gallery has put together a feast of portraiture its Mayfair premises, including works by artists already held in the National Portrait Galleries collection....
...Novartis started building its stake when it approached Roche in the early 2000s over a possible merger, pushed by then-Novartis chief Daniel Vasella, but was vetoed by the Hoffman-La Roche family that controls...
...Innova, which sells mostly Asian-made tests, is building a new production facility in Wales, but chief executive Daniel Elliott says it lacks enough contracts to be profitable after the company failed to...
...As chair of Sony’s board from 2013, he helped the entertainment group fend off an activist campaign by Daniel Loeb and strengthened its governance structure....
...The FT’s Tim Hayward and Daniel Garrahan travel to rural Scotland to see how one farm-to-fork restaurant has navigated the crisis....
...Co-founder and general manager Jean-Daniel Kuhn says that though others are printing in mortar, using robot arms to pipe layer upon layer — like icing a cake over and over — XtreeE has developed a patented...
...Shares in Roche, whose subsidiary Genentech makes gantenerumab, were flat....
...A little before that house was built, Daniel Defoe published a poem reminding his compatriots that there was no such thing as “The True-Born Englishman”, but instead “a mongrel half-bred race . . ....
...Daniel Hoffman, a former clandestine officer who served as station chief in three locations and counts Ms Haspel as a friend, said he left the agency to spend more time with his family after three decades...
...Daniel O’Day, chief executive of Gilead, which has been donating supplies of remdesivir as a treatment that can accelerate recovery from the disease, concurs....
...Daniel Salas, Costa Rica’s health minister, told the Financial Times he was hopeful the WHO would soon go ahead with the plan....
...Pharmaceutical groups, which rely heavily on mainland Europe for drugs, have stockpiled, with GlaxoSmithKline, Switzerland’s Roche and France’s Sanofi reporting weeks or even months of extra supplies....
...Speed of testing Testing needs to be sped up from the initial manual processes, using high throughput machines developed by companies such as Roche and ThermoFisher, where each machine can do between 1,000...
...US drugmaker Gilead Sciences has poached pharmaceutical industry veteran Daniel O’Day from Swiss rival Roche to be its new chief executive as it battles to revive flagging sales....
...It comes as Gilead is under pressure from sliding sales of its blockbuster hepatitis C drug, and is the first major move by chief executive Daniel O’Day who joined from Roche Pharmaceuticals in March....
...“Every day between now and the first human testing is mapped out and precious,” says Daniel Skovronsky, chief medical officer of Eli Lilly....
....* Nat Turner, the chief executive of Flatiron Health, the cancer data and research company which was acquired by the established Swiss-based drug company Roche last year for $1.9bn, was there....
...Novartis completed the acquisition of Alcon in 2010 as part of a healthcare empire-building spree by former chief executive Daniel Vasella....
...Daniel O’Day, head of Roche’s pharmaceuticals division, said Roche believed “molecular insights and the broad availability of high quality comprehensive genomic profiling are key enablers for the development...
...Daniel O’Day, head of pharma for Roche and one of the industry’s most high profile figures, announced last month that he was leaving the Swiss drugmaker to take the helm at Gilead Sciences....
International Edition